Core Viewpoint - A dispute has arisen between two A-share companies regarding the exclusive distribution rights of the AestheFill product, with *ST Suwu asserting its rights against Regen Biotech, a subsidiary of Aimeike [2][3] Group 1: Dispute Details - *ST Suwu claims that Regen Biotech intends to terminate the exclusive distribution agreement for AestheFill in mainland China, citing alleged violations of the agreement by *ST Suwu and its executives [2][3] - Regen Biotech has sent a termination notice to *ST Suwu, asserting that the latter has transferred the distribution rights to its controlling shareholder, Wu Zhong Meixue, which they claim violates the agreement [2][3] - *ST Suwu refutes these claims, stating that there has been no transfer of rights and that the exclusive distribution agreement remains legally binding until 2032 [3] Group 2: Product and Market Impact - AestheFill is a regenerative injection product developed by Regen Biotech, primarily composed of PDLLA microspheres and sodium carboxymethyl cellulose, aimed at skin rejuvenation [4] - The product was first approved for sale in South Korea in 2014, and *ST Suwu acquired a 51% stake in the distributor, Dato Medical, in 2021 for 166 million yuan [4][5] - AestheFill generated significant revenue for *ST Suwu, contributing 3.26 billion yuan to the company's total revenue in 2024, accounting for 20.42% of total revenue and 34.80% of gross profit [6] Group 3: Corporate Developments - Aimeike recently acquired 85% of Regen Biotech for approximately 1.386 billion yuan, gaining control over the company and integrating it into its financial statements [5][6] - The sales performance of AestheFill is critical for *ST Suwu, especially as the company faces a potential delisting due to regulatory issues related to financial misreporting [6]

Core Viewpoint - The dispute over the agency rights for the "Youthful Needle" AestheFill has escalated, with Jiangsu Wuzhong's subsidiary receiving a termination notice from REGEN, which will revoke its exclusive distribution rights in mainland China [1][2]. Group 1: Company Impact - Jiangsu Wuzhong's subsidiary, Datou Medical, received a termination letter from REGEN, which will withdraw all related authorizations for AestheFill's exclusive distribution in mainland China [1]. - AestheFill generated revenue of 326 million yuan within six months of its launch in April 2024, contributing to Jiangsu Wuzhong's turnaround with a net profit of 70 million yuan last year [1]. - The revenue for AestheFill reached 113 million yuan in the first quarter of this year, highlighting its significance for Jiangsu Wuzhong, which is already facing challenges due to previous financial misreporting [1]. Group 2: Market Dynamics - The announcement from Jiangsu Wuzhong on July 17 claimed that the medical beauty business was operating normally and that the change in registration agent would not affect the exclusive agency rights, only to be contradicted by the termination notice from REGEN the following day [2]. - The change of the registration agent from Datou Medical to Lizhen Biotechnology, a company controlled by REGEN, suggests prior negotiations that Jiangsu Wuzhong did not disclose, raising questions about their information disclosure practices [3]. - The market for "Youthful Needles" is becoming increasingly competitive, with multiple approvals for similar products from various companies, including four new products approved in less than seven months this year [7][8].

Core Insights - JD Health has launched its first offline self-operated medical beauty clinic named "JD Medical Beauty (Yizhuang Store)" in Beijing, which is now integrated into the JD App's medical beauty channel and has a WeChat mini-program [2] - The second self-operated medical beauty clinic, "Guomao Store," is in preparation and is expected to open on September 30 [2] - The JD Medical Beauty flagship store on the JD App has attracted 280 followers, offering services ranging from anti-oxidation to facial treatments, with prices ranging from 99 yuan to 2439 yuan [3] Company Strategy - Unlike its expansion strategies in other sectors, JD has not introduced subsidy policies for its medical beauty services, focusing instead on cost-effective pricing to attract price-sensitive consumers [5] - Future expansion plans are in place, but specific city opening schedules have not yet been determined [5] - JD has laid the groundwork for its medical beauty business since September 2021, collaborating with New Oxygen to launch a medical beauty channel and establishing a medical beauty subsidiary in March 2025 [5] Market Context - The medical beauty market in China is rapidly growing, with a market size exceeding 500 billion yuan and a compound annual growth rate of over 20% expected by 2024 [7] - JD faces significant competition from other internet giants, such as Meituan and Alibaba, which have established their own medical beauty strategies [7] - As consumer demands for medical beauty services evolve, there is an increasing emphasis on service quality, safety, and compliance, posing challenges for JD as a latecomer in the industry [7][8]

金十数据7月21日讯，国泰海通发布研报称，产品创新是新消费的重要方向，医美、化妆品品类对成分 技术更加强调，上游产品线不断完善，新品加速落地推动行业出新。整体来看，美护板块成长属性明 显，基本面维度品牌分化加剧，建议自下而上优选存在产品及渠道变化、具备弹性的标的。 国泰海通：美护板块成长属性明显，基本面维度品牌分化加剧 ...

Core Insights - The medical beauty injection market is rapidly transforming the industry landscape, driven by minimally invasive procedures, quick recovery, and broad applicability, making it the most promising segment in the medical beauty field [1] - The regenerative injection market in mainland China is projected to maintain a high compound annual growth rate of 54.73%, with an expected market size exceeding 11.52 billion yuan by 2027, reflecting explosive consumer demand and accelerated technological innovation [1] Company Developments - Four Seasons Pharmaceutical's stock price has risen against the trend, primarily due to strong growth signals from its dual focus on medical beauty and innovative drugs [2] - The company launched three new regenerative medical beauty products, which are expected to fill clinical technology gaps and rapidly capture market share, thus injecting new momentum into its medical beauty business [2] - The innovative drug sector is also progressing, with the approval of a CDK4/6 inhibitor for late-stage breast cancer, enhancing market confidence and supporting the company's valuation [2] Industry Trends - The regenerative medical beauty sector is entering a "new product explosion period," marked by a surge in regulatory approvals and innovations [1][2] - The industry is shifting towards a comprehensive service system that combines aesthetic and psychological value, moving beyond mere external improvements [5] Product Innovations - The newly launched products, including 回颜臻® (Youthful Needle), 斯弗妍® (Youthful Needle), and 倾研® (Youthful Needle), are designed to activate the skin's collagen regeneration system, offering long-lasting effects rather than temporary solutions [11][12] - These products utilize advanced technologies to ensure precise targeting and effective results, transforming the approach to anti-aging treatments [11][12] Strategic Vision - Four Seasons Pharmaceutical emphasizes a commitment to continuous innovation and technological breakthroughs, aiming to redefine the boundaries of anti-aging aesthetics [15] - The company is focused on creating a comprehensive ecosystem for skin rejuvenation, integrating various treatment modalities to meet diverse consumer needs [7][8]

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, highlighting innovative business models driving growth in the light medical beauty sector, particularly recommending attention to the company "Xinyang" [2][9]. Core Insights - The cosmetics and medical beauty sector has underperformed the market recently, with the Shenwan Beauty Care Index declining by 0.1% from July 11 to July 18, 2025, while the Shenwan Cosmetics Index fell by 0.9%, underperforming the Shenwan A Index by 2.3 percentage points [3][4]. - Innovative business models are driving growth in light medical beauty, contrasting with traditional medical beauty institutions facing stagnation due to high costs and weak consumer demand. Xinyang's high cost-performance ratio, chain operations, and app-based customer conversion model are seen as new growth drivers for the sector [9][10]. - The report emphasizes the importance of supply-side innovations in stimulating consumer demand and driving industry recovery, despite short-term macroeconomic challenges [9]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has shown weak performance compared to the market, with specific indices reflecting declines during the reporting period [3][4]. - The top-performing stocks in the sector included Zhongshun Jierou (+10.8%) and Juzibio (+6.1%), while the worst performers were Shangmei Shares (-11.1%) and Baiya Shares (-4.3%) [5]. Key Company Insights - Linqingxuan, a high-end domestic skincare brand, has seen revenue growth from 690 million yuan in 2022 to 1.21 billion yuan in 2024, with net profit turning from a loss of 6 million yuan to a profit of 187 million yuan [10][15]. - The company has established a strong product matrix and supply chain advantages, with production capacity reaching 40 million units annually [16][17]. - The report also highlights the growth of the "Plant Doctor" brand, which has achieved a net profit CAGR of 24% from 2022 to 2024, supported by a robust channel network and operational efficiencies [10][12]. Market Trends - The report notes a shift in the cosmetics market from quantity to quality, with a significant increase in e-commerce sales, which accounted for 47% of total cosmetics sales in 2024, up from 22% in 2016 [11]. - The domestic market is witnessing a rise in local brands, with a notable increase in market share for domestic products, reflecting changing consumer preferences and the impact of the "national tide" [11][28]. Financial Performance - The report indicates that the overall retail sales of cosmetics in China reached 229.1 billion yuan in the first half of 2025, with a year-on-year growth of 2.9%, although June saw a decline of 2.3% due to promotional timing [21][24]. - The performance of major companies like Meili Tianyuan is highlighted, with projected revenue of at least 1.45 billion yuan for the first half of 2025, representing a growth of at least 27% [24].

Summary of the Conference Call for Xinyang Company Overview - Xinyang has an estimated valuation of approximately 800 million RMB after acquiring Jizhi Laser and is acting as an agent for 11 Korean hyaluronic acid products. The company operates 32 Xinyang Youth Clinics and plans to expand to 50 clinics by the end of 2025, focusing on franchise openings in second and third-tier cities [2][3][10]. Industry Insights - The non-surgical segment of China's light medical beauty market has reached 70%-80% market share, with intense competition in the hyaluronic acid market. Xinyang effectively controls customer acquisition costs, averaging 600 RMB, significantly lower than traditional medical beauty institutions [2][4][7]. - The light medical beauty market is expected to see over 2,000 institutions in China, based on the penetration rate observed in South Korea [5]. Financial Performance - Xinyang's total revenue for 2023 and 2024 is projected to be around 1.5 billion RMB, with chain revenue of 170 million RMB in 2024 and nearly 100 million RMB in Q1 2025. The company anticipates achieving profitability in Q4 2025 [4][10][25]. Business Model and Expansion Strategy - Xinyang's business model consists of three main segments: an internet platform (Xinyang APP), upstream products (including the acquisition of Jizhi Laser), and downstream light medical beauty chain brand Xinyang Youth Clinics [3][4]. - The company plans to open 50 new clinics by the end of 2025, with a focus on second and third-tier cities, and aims to maintain a rapid expansion pace [20][31]. Operational Efficiency - Xinyang has streamlined its SKU offerings, focusing on standardized projects like phototherapy and anti-aging injections, which enhances operational efficiency [2][13]. - The average customer acquisition cost is only 600 RMB, compared to 30%-50% of total costs for traditional medical beauty institutions [7][15]. Product Development and Supply Chain - Xinyang is set to launch new water light and picosecond devices in the second half of 2025, with plans for new generation products in 2026-2027 [8][16]. - The company has invested significantly in supply chain management, securing exclusive rights to upstream manufacturers, which allows for better pricing and cost control [16][27]. Competitive Advantages - Xinyang's advantages over competitors include a strong internet platform, proprietary products, and a robust team of professional doctors, which enhance cost-effectiveness and market competitiveness [11][19]. - The company believes that the entry of giants like JD Health into the medical beauty sector will not pose significant competitive pressure due to their lack of brand recognition and medical resources [23]. Customer Retention and Marketing - Xinyang employs private domain operations and pricing advantages to enhance user satisfaction and acquisition effectiveness, with a significant portion of customer acquisition coming from private channels [14][15]. - The company has a structured approach to doctor training and team building, ensuring high-quality service delivery [35]. Challenges and Future Outlook - Xinyang faces challenges in standardizing offerings due to the high skill requirements for personalized aesthetic services. The company is addressing this by focusing on easily standardized projects [13]. - The company is optimistic about achieving profitability in Q4 2025, despite current losses due to heavy investments in chain business development [25][36]. Conclusion - Xinyang is strategically positioned in the rapidly growing light medical beauty market in China, with a clear expansion plan, operational efficiencies, and a focus on product development. The company is well-equipped to navigate competitive pressures and capitalize on market opportunities.

Group 1: Travel Market Response - The travel market is experiencing a surge in demand as high school graduates seek to celebrate their achievements with family trips, particularly to historical and cultural cities like Beijing, Nanjing, and Xi'an [2][3] - Popular travel destinations include theme parks, with Shanghai Disney Resort being a top choice, and many regions are offering discounts for graduates, such as free entry with exam admission tickets [2][3] - Approximately 55% of graduation trip users prefer to travel in groups of 2 to 3, highlighting the trend of shared experiences among friends and family [2] Group 2: Skills and Personal Development - Graduates are increasingly investing in personal development activities such as driving lessons, fitness training, and skill enhancement courses during their break [4] - Training institutions are offering summer discounts to attract graduates, with driving schools providing significant fee reductions for students [4] - The end of high school marks a transition to adulthood for many graduates, leading to increased consumer autonomy and spending on personal grooming and medical aesthetics [4][6] Group 3: Consumer Behavior Insights - The post-exam economy reflects a balance between material and experiential consumption, with a focus on both immediate enjoyment and long-term human capital investment [5] - There is a notable shift towards rational purchasing behavior among graduates, with many opting for essential items rather than luxury brands, influenced by promotional offers and discounts [7] - The interest in domestic brands among the "00s" generation is rising, with a reported 78% purchasing rate, indicating a significant opportunity for local brands [6][7] Group 4: Sustainable Consumption Practices - Experts emphasize the importance of guiding young consumers towards rational spending, encouraging them to balance their desires with financial realities [6] - The government and businesses are urged to adapt to the evolving consumer landscape by enhancing product offerings and ensuring a safe consumption environment [7] - Sustainable development of the post-exam economy requires a focus on long-term consumer needs and preferences, with an emphasis on innovation in products and services [7]

Core Viewpoint - The article discusses the rising trend of cosmetic procedures among high school graduates during the summer after college entrance examinations, highlighting both the appeal and the associated risks of medical beauty treatments [1][9]. Group 1: Trends in Cosmetic Procedures - There is a noticeable increase in the number of high school graduates seeking cosmetic procedures, with patient numbers rising by approximately 30% during the summer following the college entrance exams [2][3]. - Popular procedures among high school graduates include double eyelid surgery, facial slimming injections, and laser treatments for acne and blemishes [4][5]. Group 2: Marketing Strategies by Medical Institutions - Medical institutions, both public and private, are actively promoting special offers targeting high school graduates, with discounts ranging from 60% to 80% on various cosmetic procedures [5]. - Social media discussions around cosmetic procedures as rewards for academic achievements are prevalent, indicating a cultural shift towards valuing appearance among young adults [5][12]. Group 3: Risks and Concerns - Experts warn that many cosmetic procedures may not be suitable for high school graduates, emphasizing the need for proper assessments before undergoing surgery [9][11]. - There are significant risks associated with cosmetic procedures, including potential psychological impacts and complications from unregulated practices, as illustrated by cases of patients suffering from adverse effects after seeking low-cost treatments [8][12]. Group 4: Recommendations for Parents and Youth - Experts recommend that parents guide their children in understanding the risks of cosmetic procedures and help them develop a healthy self-image [13]. - It is advised that both parents and students seek information from qualified medical institutions and be cautious of misleading advertisements that may encourage impulsive decisions regarding cosmetic enhancements [12][13].

Core Viewpoint - The article discusses the rising anxiety among young people regarding aging and the subsequent rush to medical beauty institutions, often leading to poor decisions and potential risks in treatments [3][4]. Group 1: Industry Trends - There is a growing trend of anxiety related to aging, amplified by social media, prompting individuals to seek medical beauty treatments urgently [3]. - Many consumers have become vulnerable to misleading practices in the medical beauty industry, often resulting in unnecessary treatments and high costs [4][6]. - The medical beauty industry is characterized by a mix of legitimate practices and unregulated operations, with illegal practitioners outnumbering compliant ones significantly [30][32]. Group 2: Consumer Trust and Verification - Platforms like Meituan's "放心美" (Safe Beauty) are implementing strict verification processes for medical beauty institutions, enhancing transparency and consumer trust [7][10]. - The "放心美" initiative connects directly with official data, allowing consumers to verify the legitimacy of treatments and products easily [10][41]. - The initiative has reportedly led to over 700 million verification instances, indicating a strong consumer response to the need for trust in medical beauty services [34]. Group 3: Doctor Selection and Accountability - Consumers now have access to verified information about doctors, including their qualifications and experience, which helps in making informed decisions [22][24]. - The verification process allows consumers to assess the credibility of medical professionals, reducing the reliance on institutional claims [22][23]. - The article emphasizes the importance of transparency in the selection of medical professionals, as consumers prefer to avoid risks associated with unqualified practitioners [24][42]. Group 4: Regulatory Environment - The article highlights the disparity between compliant medical beauty institutions and illegal operations, with the latter often engaging in aggressive pricing strategies due to lower operational costs [29][30]. - The medical beauty industry is undergoing a transformation towards greater compliance and transparency, driven by consumer demand for safety and quality [44][50]. - Meituan's initiatives, including the "北极星榜单" (North Star List) and "司南医生榜" (Compass Doctor List), aim to enhance the credibility of medical beauty services by providing objective assessments of institutions and practitioners [46][48].